MASI2.0: Insights of Microbiota Metabolic Potential from Incorporating Genomic Information on Microbiota-Active...

Extensive interactions between microbiota and active substances are health- and disease-relevant. Mechanistic understanding from genomic perspective of these interactions and potential impacts is important for biomedical and pharmaceutical research. However, current data repositories often lack systematic integration from a genomic perspective. Here we describe an update of the MASI microbiota-active substance interactions database. This update includes new data of (1) genomic-derived 166,766 microbiota-drug interactions and 205,505 microbiota-food interactions linked by 415 biosynthetic gene clusters (BGCs), 59 metabolic gene clusters (MGCs), and 7250 genome-scale metabolic network models (GEMs) of ∼1200 microbiota species, and (2) 1848 microbiota-microbiota interaction records mediated by 39 quorum sensing languages, and (3) 46,717 microbiota-disease associations between 640 species and 59 diseases. Overall, this update provides 44,643 interasctions derived from ∼2000 publications and 380,571 genome-derived interactions, covering 1867 microbe species, 1576 therapeutic substances, 357 dietary substances, which is freely accessible at https://www.aiddlab.com/MASI2025/index.html.